MEMORIAL SLOAN KETTERING CANCER CENTER - Synovial Sarcoma Survival
Our synovial sarcoma nomogram is a tool designed to predict the likelihood of surviving three years and five years after being diagnosed with synovial sarcoma, based on clinical and pathologic factors known before surgery. This tool is not designed for patients who received chemotherapy with anthracycline and ifosfamide (AI) before or shortly after surgery, as the nomogram predictions may be inaccurate.
MEMORIAL SLOAN KETTERING CANCER CENTER - Liposarcoma Survival After Initial Surgery
Our liposarcoma nomogram is a tool designed to predict the prognosis of a patient with liposarcoma, the most common soft tissue sarcoma, after the primary tumor has been removed by surgery. This tool predicts the likelihood of surviving five years and 12 years after surgery, based on the characteristics of the patient and the tumor, such as the specific liposarcoma histologic subtype.
MEMORIAL SLOAN KETTERING CANCER CENTER - Extremity Sarcoma: Risk of Local Recurrence After Limb-Sparing Surgery Without Radiation
Our sarcoma local recurrence nomogram is a tool designed to predict the likelihood of soft tissue sarcoma returning at the site of initial surgery after the tumor is removed through limb-sparing surgery if the patient does NOT receive radiation. The probability of local recurrence is calculated for both three years and five years after surgery.
MEMORIAL SLOAN KETTERING CANCER CENTER - Sarcoma-Specific Death After Local Recurrence
Our nomogram for sarcoma-specific death after local recurrence is a tool designed to predict the likelihood of dying from sarcoma after local recurrence of the initially treated soft tissue sarcoma. This tool predicts the likelihood of dying one year, two years, three years, four years, and five years after recurrence.
MEMORIAL SLOAN KETTERING CANCER CENTER - Sarcoma-Specific Death After Surgery
Our postoperative sarcoma-specific death nomogram is a tool designed to predict the likelihood of dying from soft tissue sarcoma four years, eight years, and 12 years after surgical treatment for the disease.
MEMORIAL SLOAN KETTERING CANCER CENTER - Desmoid Fibromatosis: Local Recurrence-Free Survival After Surgery
Our desmoid fibromatosis local recurrence nomogram is a tool designed to predict the likelihood of survival without the desmoid tumor returning at the site of initial surgery after the tumor is removed through surgery. The probability of survival free of local recurrence is calculated for three years, five years, and seven years after surgery.
MEMORIAL SLOAN KETTERING CANCER CENTER - Uterine Leiomyosarcoma Nomogram
Our uterine leiomyosarcoma nomogram is a prediction tool designed to help patients and their physicians calculate the likely outcome of their surgical treatment for uterine leiomyosarcoma, a type of uterine cancer. It is not appropriate for patients who have not had surgery to remove their uterine leiomyosarcoma.
MEMORIAL SLOAN KETTERING CANCER CENTER - Gastrointestinal Stromal Tumor Nomogram
Our gastrointestinal stromal tumor nomogram is a prediction tool designed to help patients and their physicians calculate the likelihood of tumor recurrence following the complete resection (surgical removal of all cancerous tissue) of the gastrointestinal stromal tumor. It is designed for patients who have not received tyrosine kinase inhibitors before or after surgery.
THE LIFE RAFT GROUP - Risk of Recurrence
Many attempts have been made to classify GISTs as to their potential for malignant behavior. However, Pathologists who are GIST experts, currently think it most prudent to classify GISTs based on risk assessment, rather than try to classify them as benign or malignant. At least some GIST experts think it is unwise to use the term “benign” with GIST and that almost all GISTs should be considered as having some malignant potential.
Sarculator
This app is designed to be used by doctors, not to take clinical decisions (the clinical utility of the two models has not been proved yet), but it can be used as an informative tool to improve the capacity of prediction of the physicians.
There are two kinds of predictions:
• RPS: 7 years of global survival (GS) and 7 years of disease-free survival (DFS) on patients with retroperitoneal area primary resected sarcoma.
• STS: global survival at 5 and 10 years and accumulated incidence of distant metastasis on patients with resected primary limb sarcoma.
More information: http://www.sarculator.com/
